FindTrial
Sign In

LYNOZYFIC 5 mg concentrate for solution for infusion

DRUG4 trials

Sponsors

Regeneron Pharmaceuticals Inc., European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale, Region Hovedstaden

Conditions

Haematological diseases; any disorder that primarily affects the bloodNewly Diagnosed Transplant Ineligible Multiple Myeloma PatientsRelapsed Refractory Multiple MyelomaRelapsed/Refractory Multiple Myelomabone marrowthe lymphatic system and/or blood-forming organs.

Phase 1

A FIRST-IN-HUMAN (FIH) PHASE 1/2 STUDY TO ASSESS SAFETY, TOLERABILITY, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF REGN17372, AN ANTI-GPRC5D X ANTI-CD28 COSTIMULATORY BISPECIFIC MONOCLONAL ANTIBODY, IN COMBINATION WITH LINVOSELTAMAB, AN ANTI-BCMA X ANTI-CD3 BISPECIFIC MONOCLONAL ANTIBODY, IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Not yet recruitingCTIS2025-522776-93-00
Regeneron Pharmaceuticals Inc.Relapsed/Refractory Multiple Myeloma
Target: 26Updated: 2026-04-22

Phase 3

A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab Versus continued Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
RecruitingCTIS2024-519827-16-00
European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa SocialeNewly Diagnosed Transplant Ineligible Multiple Myeloma Patients
Start: 2025-09-30Target: 713Updated: 2025-11-25
An Open-label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab plus Carfilzomib versus Standard of Care Combination Regimens in Patients with Relapsed/Refractory Multiple Myeloma
Not yet recruitingCTIS2024-519504-27-00
Regeneron Pharmaceuticals Inc.Relapsed Refractory Multiple Myeloma
Target: 40Updated: 2026-02-10

Phase 4

A multicentre, adaptive, randomised, multidomain, platform trial for dose optimization in the treatment of adult patients with haematological diseases (BLOOD-dose): core protocol
Not yet recruitingCTIS2026-525658-13-00
Region Hovedstadenbone marrow, Haematological diseases; any disorder that primarily affects the blood, the lymphatic system and/or blood-forming organs.
Target: 200Updated: 2026-06-25